<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03779113</url>
  </required_header>
  <id_info>
    <org_study_id>2018-523-00US1</org_study_id>
    <nct_id>NCT03779113</nct_id>
  </id_info>
  <brief_title>An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma</brief_title>
  <official_title>A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hutchison Medipharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hutchison Medipharma Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients&#xD;
      with relapsed or refractory lymphoma who have exhausted approved therapy options. This study&#xD;
      consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients&#xD;
      with relapsed or refractory lymphoma who have exhausted approved therapy options. This study&#xD;
      consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).&#xD;
&#xD;
      Dose Escalation Stage (Stage 1)&#xD;
&#xD;
      Dosing will begin at 100 mg once daily (QD). A cycle of study treatment will be defined as 28&#xD;
      days of continuous dosing. The modified 3+3 design will be applied for dose escalation and&#xD;
      MTD determination to limit the number of patients exposed to potentially ineffective or&#xD;
      unsafe doses. The study will enroll 1 patient and the patient will be treated for a 28-day&#xD;
      cycle in the initial dose cohort. If there is no Dose Limiting Toxicity (DLT) and no more&#xD;
      than 2 treatment-emergent adverse events (TEAEs) of Common Terminology Criteria for Adverse&#xD;
      Events (CTCAE) Grade ≥2 in the first treatment cycle, the study will be escalated to the next&#xD;
      dose cohort and continue with the standard 3+3 design. Otherwise, the trial will revert to a&#xD;
      standard 3+3 design from the initial dose cohort. A minimum of 3 patients will be enrolled&#xD;
      and observed for toxicity in each successive dose cohort after the initial dose cohort. If&#xD;
      the 3 patients initially enrolled in a given dose cohort complete the DLT assessment window&#xD;
      (Cycle 1, Days 1-28) without experiencing a DLT, 3 patients will be enrolled at the next&#xD;
      higher dose level. If 2 or more of the initial 3 patients enrolled at any dose level&#xD;
      experience a DLT during the DLT assessment window, the dose escalation will be halted. If 1&#xD;
      of the initial 3 patients enrolled at any dose level experiences a DLT during the DLT&#xD;
      assessment window, additional patients will be enrolled at that dose level for a minimum of 6&#xD;
      evaluable patients for DLT. If a DLT is observed in 1 of the 6 valuable patients at this dose&#xD;
      level, dose escalation will proceed to the next pre- defined dose level. If DLTs are observed&#xD;
      in 2 or more of the 6 evaluable patients at a given dose level, the dose escalation will be&#xD;
      halted. If the dose escalation is completed due to 2 or more DLTs at a dose level and that&#xD;
      dose level is ≥50% higher than the previous dose level, then an intermediate dose level may&#xD;
      be evaluated for toxicity in the same manner as described above. If the dose level is &lt;50%&#xD;
      higher than the previous dose level, in which only 3 DLT evaluable patients were enrolled, 3&#xD;
      additional patients will be enrolled at that dose level to comprise 6 DLT evaluable patients.&#xD;
&#xD;
      The proposed dose escalation scheme comprises Cohorts 1 to 5 with dosing levels of 100 mg QD,&#xD;
      200 mg QD, 400 mg QD, 600 mg QD and 800 mg QD, respectively. The need for dose escalation&#xD;
      beyond 800 mg QD, the specific dose to be tested and the potential for twice-daily (BID)&#xD;
      dosing will be evaluated jointly by investigators and the sponsor based on the cumulative&#xD;
      clinical safety, pharmacokinetic, and preliminary efficacy data. Safety monitoring and&#xD;
      evaluation of dose escalation will be carried out by the Safety Review Committee, which will&#xD;
      be comprised of the sponsor's study team members (including medical monitor, safety monitor&#xD;
      and and Pharmacokinetic scientist) and the site principal investigators. The adverse event&#xD;
      profile and serum concentration of HMPL-523 data will be evaluated to determine whether it is&#xD;
      safe to continue the assigned HMPL-523 dose for dose escalation or whether the dose should be&#xD;
      de-escalated to the lower dose level.&#xD;
&#xD;
      Dose Expansion Stage (Stage 2)&#xD;
&#xD;
      The adverse event profile, serum concentration, and preliminary anti-tumor activity of&#xD;
      HMPL-523 at the maximum tolerated dose(MTD)/recommended phase 2 dose(RP2D) will be further&#xD;
      evaluated in approximately 50 patients with relapsed or refractory indolent B-cell&#xD;
      non-Hodgkin's lymphomas. The tumor types of the dose expansion stage are restricted to:&#xD;
&#xD;
        -  10 patients with chronic lymphocytic leukemia/small lymphocytic lymphoma&#xD;
&#xD;
        -  10 patients with mantle cell lymphoma&#xD;
&#xD;
        -  10 patients with follicular lymphoma (Grade 1-3a)&#xD;
&#xD;
        -  10 patients with marginal zone lymphoma&#xD;
&#xD;
        -  10 patients with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma.&#xD;
&#xD;
      Patients will receive HMPL-523 at the MTD/RP2D for continuous 28-day treatment cycles until&#xD;
      disease progression, death, intolerable toxicity, at investigator's discretion that the&#xD;
      patient can no longer benefit from the study treatment, patient withdrawal from the study, or&#xD;
      the end of study, whichever comes first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0</measure>
    <time_frame>From first dose to within 30 days after the last dose</time_frame>
    <description>The safety and tolerability of HMPL-523 will be evaluated based on adverse events data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>From Cycle 1, Day 1, 5 min pre-dose 1st dose until Cycle 1, Day 28 8 hours post-dose.</time_frame>
    <description>To Characterize the pharmacokinetic properties of HMPL-523 in patients with relapsed or refractory lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in a selected time interval (AUC0-t)</measure>
    <time_frame>From Cycle 1, Day 1, 5 min pre-dose 1st dose until Cycle 1, Day 28 8 hours post-dose.</time_frame>
    <description>To characterize the pharmacokinetic properties of HMPL-523 in patients with relapsed or refractory lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR) defined as the proportion of patients who have a CR or PR</measure>
    <time_frame>From first dose to within 30 days after the last dose</time_frame>
    <description>To evaluate the anti-tumor activity of HMPL-523 in patients with relapsed or refractory lymphoma according to: (1) Chronic Lymphocytic Leukemia (CLL) - modified International Workshop on CLL guidelines, (2) Waldenstrom's Macroglobulinemia (WM) - consensus of international workshops on WM, (3) Lymphomas other than CLL or WM: Lugano Response Criteria for Hodgkin and Non-Hodgkin's Lymphoma.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients to received study drug (HMPL-523)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMPL-523</intervention_name>
    <description>Oral HMPL-523</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet the following criteria to be eligible for study entry:&#xD;
&#xD;
          1. Signed informed consent form (ICF).&#xD;
&#xD;
          2. Age ≥18 years.&#xD;
&#xD;
          3. ECOG performance status of 0 or 1.&#xD;
&#xD;
          4. Histologically confirmed lymphoma, including Hodgkin's lymphoma and non-Hodgkin's&#xD;
             lymphoma. In the dose expansion stage, the tumor types are restricted to relapsed or&#xD;
             refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, mantel cell&#xD;
             lymphoma, follicular lymphoma (Grade 1-3a), marginal zone lymphoma, and Waldenstrom's&#xD;
             macroglobulinemia/lymphoplasmacytic lymphoma.&#xD;
&#xD;
          5. Patients with relapsed or refractory lymphoma who have exhausted all approved therapy&#xD;
             options.&#xD;
&#xD;
          6. In the dose expansion stage, patients must have measurable disease for an objective&#xD;
             response assessment, except for patients with chronic lymphocytic leukemia and&#xD;
             Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.&#xD;
&#xD;
          7. Expected survival of more than 24 weeks as determined by the investigator.&#xD;
&#xD;
          8. Male or female patients of child-bearing potential must agree to use double barrier&#xD;
             contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device,&#xD;
             contraceptives (oral or parenteral), Implanon®, injectables, or other measures to&#xD;
             avoid pregnancy during the study and for 90 days after the last day of treatment.&#xD;
             Post-menopausal females (&gt;50 years old and without menses for &gt;1 year) and women who&#xD;
             are surgically postmenopausal are exempt from this criterion.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Patients with primary central nervous system (CNS) lymphoma.&#xD;
&#xD;
          2. Any of the following laboratory abnormalities: Absolute neutrophil count&lt;1.5×10^9/L,&#xD;
             Hemoglobin &lt;80 g/L, Platelets &lt;75×10^9/L&#xD;
&#xD;
          3. Inadequate organ function, defined by the following: Total bilirubin &gt;1.5 times the&#xD;
             upper limit of normal (× ULN), aspartate aminotransferase and/or alanine&#xD;
             aminotransferase &gt;2.5 × ULN, Estimated Creatinine Clearance (CrCl) per Cockcroft-Gault&#xD;
             [Dose Escalation portion of trial (Stage 1) CrCl &lt; 50 mL/min, Dose Expansion portion&#xD;
             of trial (Stage 2) CrCl &lt; 30 mL/min], Serum amylase or lipase &gt;ULN, International&#xD;
             normalized ratio &gt;1.5 × ULN, or activated partial thromboplastin time &gt;1.5 × ULN&#xD;
&#xD;
          4. Patients with clinically detectable second primary malignant tumors at enrollment or&#xD;
             other malignant tumors within the last 2 years (with the exception of radically&#xD;
             treated basal cell or squamous cell carcinoma of the skin, in situ cervix, or in situ&#xD;
             breast cancer).&#xD;
&#xD;
          5. Any anticancer therapy, including chemotherapy, hormonal therapy, biologic therapy,&#xD;
             vaccine, or radiotherapy within 3 weeks prior to the initiation of study treatment.&#xD;
&#xD;
          6. Herbal therapy within 1 week prior to the initiation of study treatment.&#xD;
&#xD;
          7. Prior use of any anti-cancer vaccine&#xD;
&#xD;
          8. Prior treatment with any spleen tyrosine kinase (SYK) inhibitors (eg, fostamatinib)&#xD;
&#xD;
          9. Prior administration of radioimmunotherapy within 3 months before initiation of study&#xD;
             treatment.&#xD;
&#xD;
         10. Use of strong cytochrome P450 isoform 3A inhibitors and inducers and drugs metabolized&#xD;
             by cytochrome P450 isoform 3A, cytochrome P450 isoform 2B6, and cytochrome P450&#xD;
             isoform 1A2, and are identified as narrow therapeutic drugs within 7 days or 3&#xD;
             half-lives, whichever is longer, prior to initiation of study treatment&#xD;
&#xD;
         11. Adverse events from prior anticancer therapy that have not resolved to Grade ≤1,&#xD;
             except for alopecia.&#xD;
&#xD;
         12. Prior autologous stem cell transplant within 6 months prior to the initiation of study&#xD;
             treatment.&#xD;
&#xD;
         13. Prior allogeneic stem cell transplant within 6 months prior to the initiation of study&#xD;
             treatment or with any evidence of active graft versus host disease or requirement for&#xD;
             immunosuppressants within 28 days prior to the initiation of study treatment.&#xD;
&#xD;
         14. Clinically significant active infection (eg, pneumonia).&#xD;
&#xD;
         15. Major surgical procedure within 4 weeks prior to the initiation of study treatment.&#xD;
&#xD;
         16. Clinically significant history of liver disease, including cirrhosis, current alcohol&#xD;
             abuse, or current known active infection with human immunodeficiency virus, hepatitis&#xD;
             B virus, or hepatitis C virus.&#xD;
&#xD;
         17. Pregnant (positive serum beta human chorionic gonadotropin test) or lactating women.&#xD;
&#xD;
         18. New York Heart Association Class II or greater congestive heart failure.&#xD;
&#xD;
         19. Congenital long QT syndrome or correct QT interval using Fridericia's formula (QTcF)&#xD;
             &gt;480 msec&#xD;
&#xD;
         20. Current use of medication known to cause QT prolongation or Torsades de Pointes&#xD;
&#xD;
         21. History of myocardial infarction or unstable angina within 6 months prior to the&#xD;
             initiation of study treatment.&#xD;
&#xD;
         22. History of stroke or transient ischemic attack within 6 months prior to the initiation&#xD;
             of study treatment.&#xD;
&#xD;
         23. Inability to take oral medication, prior surgical procedures affecting absorption, or&#xD;
             active peptic ulcer disease.&#xD;
&#xD;
         24. Treatment in a clinical study within 30 days prior to the initiation of study&#xD;
             treatment.&#xD;
&#xD;
         25. Any other diseases, metabolic dysfunction, physical examination finding, or clinical&#xD;
             laboratory finding that, in the investigator's opinion, gives reasonable suspicion of&#xD;
             a disease or condition that contraindicates the use of an investigational drug, may&#xD;
             affect the interpretation of the results, or renders the patient at high risk from&#xD;
             treatment complications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijay Jayaprakash, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hutchison Medipharma Limited</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vijay Jayaprakash, MD</last_name>
    <phone>9739006617</phone>
    <email>vijayj@hmplglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alisha Khullar</last_name>
    <phone>973-287-3081</phone>
    <email>alishak@hmplglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Roemmich</last_name>
      <phone>864-455-3600</phone>
      <email>jRoemmich@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Cull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Martinez</last_name>
      <phone>877-632-6789</phone>
      <email>gkmartinez@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Paolo Strati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <state>Milano</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela DeLorenzo</last_name>
      <email>delorenzo.daniela@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Andres Ferreri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KO-MED Centra Kliniczne</name>
      <address>
        <city>Biała Podlaska</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominika Chwedoruk</last_name>
      <email>dominika.chwedoruk@komed-ck.pl</email>
    </contact>
    <investigator>
      <last_name>Piotr Centkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Taszner</last_name>
      <email>mtaszner@uck.gda.pl</email>
    </contact>
    <investigator>
      <last_name>Michal Taszner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BioResearch Group Sp. Z. o. o.</name>
      <address>
        <city>Kajetany</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Marek</last_name>
      <email>m.marek@bioresearch.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Jarus-Dziedzic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pratia McM</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Saweic, MD</last_name>
      <email>anna.sawiec@pratia.com</email>
    </contact>
    <investigator>
      <last_name>Wojciech Jurczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Przychodnie Medyczne</name>
      <address>
        <city>Toruń</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judyta Rudzinska</last_name>
      <email>j.rudzinska@naszlekarz.pl</email>
    </contact>
    <investigator>
      <last_name>Dominik Chraniuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mafalda Rodrigues</last_name>
      <email>amafaldanrodrigues@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Pau Abrisqueta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Valer Serra</last_name>
    </contact>
    <contact_backup>
      <last_name>avaler@iconcologia.net</last_name>
    </contact_backup>
    <investigator>
      <last_name>Eva Gonzalez Barca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Armellini</last_name>
      <email>adriana.armellini@startmadrid.com</email>
    </contact>
    <investigator>
      <last_name>Raul Cordoba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>December 10, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lymphoma</keyword>
  <keyword>mantle cell</keyword>
  <keyword>marginal zone</keyword>
  <keyword>waldenstrom</keyword>
  <keyword>chronic lymphocytic leukemia</keyword>
  <keyword>follicular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

